Biovitae has been selected as one of 15 innovative companies to take part in the Global Business Innovation Program (GBIP) – Antimicrobial Resistance (AMR), an initiative sponsored by Innovate UK, the UK Government Innovation Agency.
From February 24-28, 2025, Biovitae will have the opportunity to access one of the world’s most advanced innovation ecosystems, located in the Basel region, a nerve center of life sciences and home to some of the most important global pharmaceutical companies, including Roche, Novartis, and Sandoz.
Participation in this program is part of Biovitae’s strategy of international expansion and becoming a key player in the development of innovative solutions to combat antimicrobial resistance.
The initiative offers the opportunity to:
Gain insight into the dynamics of the Swiss market and identify new opportunities for collaboration in the AMR sector
Participate in dedicated workshops and visits to technology clusters for face-to-face discussions with experts in the field
Develop new strategic partnerships and international collaborations through targeted B2B meetings
Strengthen its value proposition to attract global investors and partners